Evidence map›Paper›PMID 25333862›Full record

ArticlePloS one2014

Malignant lymphatic and hematopoietic neoplasms mortality in Serbia, 1991-2010: a joinpoint regression analysis.

Milena Ilic, Irena Ilic

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Milena IlicDepartment of Epidemiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Irena IlicDepartment of Epidemiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
University of Kragujevac · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited data on mortality from malignant lymphatic and hematopoietic neoplasms have been published for Serbia.

methodsThe study covered population of Serbia during the 1991-2010 period. Mortality trends were assessed using the joinpoint regression analysis.

resultsTrend for overall death rates from malignant lymphoid and haematopoietic neoplasms significantly decreased: by -2.16% per year from 1991 through 1998, and then significantly increased by +2.20% per year for the 1998-2010 period. The growth during the entire period was on average +0.8% per year (95% CI 0.3 to 1.3). Mortality was higher among males than among females in all age groups. According to the comparability test, mortality trends from malignant lymphoid and haematopoietic neoplasms in men and women were parallel (final selected model failed to reject parallelism, P = 0.232). Among younger Serbian population (0-44 years old) in both sexes: trends significantly declined in males for the entire period, while in females 15-44 years of age mortality rates significantly declined only from 2003 onwards. Mortality trend significantly increased in elderly in both genders (by +1.7% in males and +1.5% in females in the 60-69 age group, and +3.8% in males and +3.6% in females in the 70+ age group). According to the comparability test, mortality trend for Hodgkin's lymphoma differed significantly from mortality trends for all other types of malignant lymphoid and haematopoietic neoplasms (P<0.05).

conclusionUnfavourable mortality trend in Serbia requires targeted intervention for risk factors control, early diagnosis and modern therapy.

Indexed as

AdolescentAdultAgedAge FactorsChildChild, PreschoolFemaleHematologic NeoplasmsHodgkin DiseaseHumansInfantInfant, NewbornLymphomaMaleMiddle AgedRegression Analysis

Identifiers

PMID25333862
PMCPMC4204851
OpenAlexW2089117834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.